Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12267174 | 1.00 | APLNR (0.44) | APLNRDGAT1MMP1MMP2MMP3 | |
| SCHEMBL15092400 | 1.00 | APLNR (0.44) | APLNRDGAT1MMP1MMP2MMP3 | |
| SCHEMBL21096068 | 0.85 | PSEN1 (0.35) | APLNRDGAT1MMP1MMP2MMP3 | |
| SCHEMBL26161883 | 0.83 | APLNR (0.45) | APLNRDGAT1ACACBFPR2PDE2A | |
| SCHEMBL8242532 | 0.83 | APLNR (0.45) | APLNRDGAT1ACACBFPR2PDE2A | |
| SCHEMBL29784759 | 0.81 | APLNR (0.48) | APLNRDGAT1PDE2A | |
| SCHEMBL18839718 | 0.81 | APLNR (0.48) | APLNRDGAT1PDE2A | |
| SCHEMBL12332374 | 0.81 | TRPA1 (0.44) | ACE2PDE2ATRPA1ALDH1A1 | |
| SCHEMBL8243599 | 0.80 | APLNR (0.43) | APLNRDGAT1MMP1MMP2MMP3 | |
| SCHEMBL16070599 | 0.79 | PDE2A (0.41) | APLNRDGAT1PDE2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453025-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2552206-B1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-22 | — | — | EP | disclosed |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | ONCOTHERAPY SCIENCE INC (JP) | 2015-07-02 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | APLNR 1318/4885DGAT1 4635/4885MMP1 3717/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | APLNR 4331/4885DGAT1 3437/4885MMP1 4437/4885 |
| US-20150183799-A1 | Tricyclic Compounds and PBK Inhibitors Containing the Same | PBDC1, SBK1, PLK2 | APLNR 4331/4885DGAT1 3437/4885MMP1 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.